MENU
+Compare
PPH
ETF ticker: NASDAQ
AS OF
Jun 12 closing price
Price
$91.78
Change
+$1.36 (+1.50%)
Net Assets
577.72M

PPH stock forecast, quote, news & analysis

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index... Show more

Category: #Health
PPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for PPH with price predictions
Jun 11, 2025

PPH in upward trend: 10-day moving average moved above 50-day moving average on May 30, 2025

The 10-day moving average for PPH crossed bullishly above the 50-day moving average on May 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 22, 2025. You may want to consider a long position or call options on PPH as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PPH just turned positive on May 19, 2025. Looking at past instances where PPH's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

PPH moved above its 50-day moving average on May 27, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PPH advanced for three days, in of 339 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PPH moved out of overbought territory on June 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PPH broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), McKesson Corp (NYSE:MCK), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Pharmaceutical ETF ETF is 145.52B. The market cap for tickers in the group ranges from 2.48B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is PDCO at 2.48B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Pharmaceutical ETF ETF was 4%. For the same ETF, the average monthly price growth was 8%, and the average quarterly price growth was 6%. BHC experienced the highest price growth at 19%, while HLN experienced the biggest fall at -1%.

Volume

The average weekly volume growth across all stocks in the VanEck Pharmaceutical ETF ETF was 0%. For the same stocks of the ETF, the average monthly volume growth was -48% and the average quarterly volume growth was 9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 37
P/E Growth Rating: 60
Price Growth Rating: 50
SMR Rating: 53
Profit Risk Rating: 64
Seasonality Score: 10 (-100 ... +100)
View a ticker or compare two or three
PPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
335 Madison Ave.19th FloorNew York
Phone
888-658-8287
Web
www.marketvectorsetfs.com